MCAM and breast carcinoma: Significantly higher levels of CD109+CECs, CD146+CECs, viable CD109+CECs and viable CD146+CECs (P = 0.0001) were found at baseline in breast cancer patients and glioblastoma patients compared to healthy controls (Table 2).